{"title":"骨质疏松症患者坚持使用双膦酸盐和降低临床椎体骨折风险:倾向评分匹配分析","authors":"Seihee Kim , Yoon-Sok Chung , Yunhwan Lee","doi":"10.1016/j.afos.2022.05.004","DOIUrl":null,"url":null,"abstract":"<div><h3>Objectives</h3><p>Bisphosphonate is associated with a decreased risk of vertebral fractures due to osteoporosis. However, there are limited studies on how poor compliance with bisphosphonate affects the risk of vertebral fractures in a nationwide cohort. We aim to evaluate whether adherence to bisphosphonate affects the risk of fracture in osteoporosis patients.</p></div><div><h3>Methods</h3><p>We used the data of the Korean National Health Insurance Service Senior Cohort. A total of 33,315 (medication possession ratio [MPR]: 50) osteoporosis patients were matched using the propensity score matching method: those who received low-dose bisphosphonate and those who received high-dose bisphosphonate. Twenty-two confounding variables, including age, socioeconomic status, medications prescribed, and underlying diseases that may affect the risk of fracture were adjusted for propensity score matching. The risk of vertebral fracture was assessed by Cox proportional hazards regression.</p></div><div><h3>Results</h3><p>Patients with a higher MPR showed a decreased vertebral fracture risk than those with a lower MPR (MPR 50 = hazard ratio [HR] 0.909; 95% confidence interval [CI] 0.877–0.942 P < 0.001; MPR 70 = HR: 0.874, 95% CI: 0.838–0.913, P < 0.001; MPR 90 = HR: 0.822, 95% CI: 0.780–0.866, P < 0.001). MPR was associated with a decreased vertebral fracture risk in both groups with or without history of fracture. In the subgroup analysis, MPR was associated with a decreased vertebral fracture risk in women, in all ages, with or without T2DM, and with or without hypertension.</p></div><div><h3>Conclusions</h3><p>Higher MPR is associated with a lower vertebral fracture risk.</p></div>","PeriodicalId":19701,"journal":{"name":"Osteoporosis and Sarcopenia","volume":"8 3","pages":"Pages 98-105"},"PeriodicalIF":2.5000,"publicationDate":"2022-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ac/55/main.PMC9577186.pdf","citationCount":"3","resultStr":"{\"title\":\"Adherence of bisphosphonate and decreased risk of clinical vertebral fracture in osteoporotic patients: A propensity score matching analysis\",\"authors\":\"Seihee Kim , Yoon-Sok Chung , Yunhwan Lee\",\"doi\":\"10.1016/j.afos.2022.05.004\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Objectives</h3><p>Bisphosphonate is associated with a decreased risk of vertebral fractures due to osteoporosis. However, there are limited studies on how poor compliance with bisphosphonate affects the risk of vertebral fractures in a nationwide cohort. We aim to evaluate whether adherence to bisphosphonate affects the risk of fracture in osteoporosis patients.</p></div><div><h3>Methods</h3><p>We used the data of the Korean National Health Insurance Service Senior Cohort. A total of 33,315 (medication possession ratio [MPR]: 50) osteoporosis patients were matched using the propensity score matching method: those who received low-dose bisphosphonate and those who received high-dose bisphosphonate. Twenty-two confounding variables, including age, socioeconomic status, medications prescribed, and underlying diseases that may affect the risk of fracture were adjusted for propensity score matching. The risk of vertebral fracture was assessed by Cox proportional hazards regression.</p></div><div><h3>Results</h3><p>Patients with a higher MPR showed a decreased vertebral fracture risk than those with a lower MPR (MPR 50 = hazard ratio [HR] 0.909; 95% confidence interval [CI] 0.877–0.942 P < 0.001; MPR 70 = HR: 0.874, 95% CI: 0.838–0.913, P < 0.001; MPR 90 = HR: 0.822, 95% CI: 0.780–0.866, P < 0.001). MPR was associated with a decreased vertebral fracture risk in both groups with or without history of fracture. In the subgroup analysis, MPR was associated with a decreased vertebral fracture risk in women, in all ages, with or without T2DM, and with or without hypertension.</p></div><div><h3>Conclusions</h3><p>Higher MPR is associated with a lower vertebral fracture risk.</p></div>\",\"PeriodicalId\":19701,\"journal\":{\"name\":\"Osteoporosis and Sarcopenia\",\"volume\":\"8 3\",\"pages\":\"Pages 98-105\"},\"PeriodicalIF\":2.5000,\"publicationDate\":\"2022-09-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/ac/55/main.PMC9577186.pdf\",\"citationCount\":\"3\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Osteoporosis and Sarcopenia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S2405525522000425\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Osteoporosis and Sarcopenia","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2405525522000425","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 3
摘要
目的:双膦酸盐可降低骨质疏松所致椎体骨折的风险。然而,在全国范围内,关于双膦酸盐依从性差如何影响椎体骨折风险的研究有限。我们的目的是评估坚持使用双膦酸盐是否会影响骨质疏松症患者骨折的风险。方法采用韩国国民健康保险服务老年人队列数据。采用倾向评分匹配法对33,315例骨质疏松患者(药物占有比[MPR]: 50)进行低剂量双膦酸盐组与高剂量双膦酸盐组的匹配。22个混杂变量,包括年龄、社会经济地位、处方药物和可能影响骨折风险的潜在疾病,被调整为倾向评分匹配。采用Cox比例风险回归法评估椎体骨折的风险。结果MPR高的患者椎体骨折风险低于MPR低的患者(MPR 50 =危险比[HR] 0.909;95%置信区间[CI] 0.877-0.942 P <0.001;MPR 70 = HR: 0.874, 95% CI: 0.838 ~ 0.913, P <0.001;MPR 90 = HR: 0.822, 95% CI: 0.780-0.866, P <0.001)。无论是否有骨折史,MPR均与椎体骨折风险降低相关。在亚组分析中,MPR与女性椎体骨折风险降低相关,不论年龄大小,不论有无T2DM,不论有无高血压。结论较高的MPR与较低的椎体骨折风险相关。
Adherence of bisphosphonate and decreased risk of clinical vertebral fracture in osteoporotic patients: A propensity score matching analysis
Objectives
Bisphosphonate is associated with a decreased risk of vertebral fractures due to osteoporosis. However, there are limited studies on how poor compliance with bisphosphonate affects the risk of vertebral fractures in a nationwide cohort. We aim to evaluate whether adherence to bisphosphonate affects the risk of fracture in osteoporosis patients.
Methods
We used the data of the Korean National Health Insurance Service Senior Cohort. A total of 33,315 (medication possession ratio [MPR]: 50) osteoporosis patients were matched using the propensity score matching method: those who received low-dose bisphosphonate and those who received high-dose bisphosphonate. Twenty-two confounding variables, including age, socioeconomic status, medications prescribed, and underlying diseases that may affect the risk of fracture were adjusted for propensity score matching. The risk of vertebral fracture was assessed by Cox proportional hazards regression.
Results
Patients with a higher MPR showed a decreased vertebral fracture risk than those with a lower MPR (MPR 50 = hazard ratio [HR] 0.909; 95% confidence interval [CI] 0.877–0.942 P < 0.001; MPR 70 = HR: 0.874, 95% CI: 0.838–0.913, P < 0.001; MPR 90 = HR: 0.822, 95% CI: 0.780–0.866, P < 0.001). MPR was associated with a decreased vertebral fracture risk in both groups with or without history of fracture. In the subgroup analysis, MPR was associated with a decreased vertebral fracture risk in women, in all ages, with or without T2DM, and with or without hypertension.
Conclusions
Higher MPR is associated with a lower vertebral fracture risk.
Osteoporosis and SarcopeniaOrthopedics, Sports Medicine and Rehabilitation, Endocrinology, Diabetes and Metabolism, Obstetrics, Gynecology and Women's Health, Geriatrics and Gerontology